Foyston Gordon & Payne Inc Buys Shares of 28,812 IQVIA Holdings Inc. $IQV

Foyston Gordon & Payne Inc bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 28,812 shares of the medical research company’s stock, valued at approximately $5,630,000.

Several other large investors have also recently made changes to their positions in IQV. International Assets Investment Management LLC purchased a new position in IQVIA in the 4th quarter valued at $27,000. Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA during the fourth quarter worth $27,000. CrossGen Wealth LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at about $28,000. Activest Wealth Management lifted its stake in shares of IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after buying an additional 118 shares in the last quarter. Finally, Financial Freedom LLC acquired a new position in IQVIA during the first quarter worth about $25,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at IQVIA

In related news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This trade represents a 15.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock valued at $3,098,793 in the last ninety days. Insiders own 1.70% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent research reports. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. JPMorgan Chase & Co. upped their price target on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research note on Thursday, July 9th. Robert W. Baird lifted their price target on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Finally, Royal Bank Of Canada boosted their price target on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Price Performance

NYSE:IQV opened at $260.17 on Friday. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $260.40. The stock’s fifty day moving average is $213.32 and its two-hundred day moving average is $187.52. The company has a market capitalization of $42.82 billion, a P/E ratio of 32.28, a P/E/G ratio of 2.21 and a beta of 1.18. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has initiated a stock buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.